Patents by Inventor Vivek Kumar Rajwanshi

Vivek Kumar Rajwanshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220048941
    Abstract: A method of making a compound represented by Formula (I): includes a reducing step, a protecting step, and a phosphitylating step, where X is NH; Y is OCF3, —O(CR42)aCR43, —O(CR42)bOCR43, or —O(CR42)b—CR4?CR42; Z is H; B is adenine (A), guanine (G), thymine (T), cytosine (C), uracil (U), 5-methylcytosine (5-me-C), or a protected version of A, G, T, C, U, or 5-me-C; each R1 is independently C1-6 alkyl or cycloalkyl; R2 is CH2CH2CN or C1-6 alkyl; or R1 and R2 together form an optionally substituted C1-6 cycloalkyl; R3 is H or PG; PG is a protecting group; R4 is independently in each instance H or F; a is 1 or 2; and b is 1, 2, or 3.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Applicant: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Jin Hong, Vivek Kumar Rajwanshi, Leonid Beigelman
  • Patent number: 11180524
    Abstract: The present disclosure relates to compounds and compositions containing 5?-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: November 23, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Jin Hong, Vivek Kumar Rajwanshi, Leonid Beigelman
  • Patent number: 11166976
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: November 9, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
  • Publication number: 20210317457
    Abstract: The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are antisense oligonucleotide (ASO) molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present disclosure provides specific ASOs that are effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.
    Type: Application
    Filed: April 9, 2021
    Publication date: October 14, 2021
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
  • Publication number: 20210189392
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 24, 2021
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong, Megan Elizabeth Fitzgerald
  • Publication number: 20210095284
    Abstract: Oligonucleotides comprising modifications at the 2 and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: March 13, 2019
    Publication date: April 1, 2021
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • Publication number: 20210040483
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: October 5, 2020
    Publication date: February 11, 2021
    Applicant: Janssen Biopharma, Inc.
    Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL
  • Publication number: 20200405743
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
  • Publication number: 20200385735
    Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 10, 2020
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
  • Patent number: 10793859
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Publication number: 20200270611
    Abstract: Modified oligonucleotides comprising a GalNAc moiety of the present disclosure along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 27, 2020
    Inventors: Sergei GRYAZNOV, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI
  • Publication number: 20200255468
    Abstract: The present disclosure relates to compounds and compositions containing 5?-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.
    Type: Application
    Filed: September 14, 2018
    Publication date: August 13, 2020
    Inventors: Sergei GRYAZNOV, Jin HONG, Vivek Kumar RAJWANSHI
  • Patent number: 10696708
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Publication number: 20200147124
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.
    Type: Application
    Filed: November 7, 2019
    Publication date: May 14, 2020
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
  • Publication number: 20180194793
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: February 13, 2018
    Publication date: July 12, 2018
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Patent number: 9932363
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 3, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Publication number: 20170002037
    Abstract: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 5, 2017
    Inventors: Leonid Beigelman, David Bernard Smith, Jerome Deval, Vivek Kumar Rajwanshi
  • Publication number: 20160318967
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 3, 2016
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Publication number: 20160264610
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Inventors: Leonid Beigelman, Jerome Deval, David Bernard Smith, Guangyi Wang, Vivek Kumar Rajwanshi
  • Patent number: 9422322
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 23, 2016
    Assignee: Alios BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi